There's no question that this is a multifactorial problem. David Wiens spoke about our multisectoral coalition that authored the white paper. That white paper highlighted many of the critical roadblocks within the regulatory framework, such as access to different types of antimicrobials and how categorization could negatively impact vaccines and vaccine technology.
However, much of this boils down to how attractive a location Canada is. When we look around the world at innovation and innovation that is coming into the animal health sector, we see that we are nobody's first choice. They are going to other countries where things are easier, where markets are larger and where impediments are fewer. We are a smaller market. We have to make ourselves attractive to some of the larger players in a different way. We have to innovate in this space, or we're going to be left behind.
